Biocon

India's largest biopharmaceutical company and global biosimilars leader

Company Overview

Biocon is India's largest biopharmaceutical company and one of the world's leading biosimilars manufacturers. Founded by Kiran Mazumdar-Shaw, Biocon has developed a portfolio of biosimilar products for diabetes, oncology, and immunology that serve patients in over 120 countries. The company's subsidiary Biocon Biologics merged with Viatris's biosimilar business to create a global biosimilars powerhouse.

Sectors

BiosimilarsBiopharmaceuticalsDiabetes Care

Primary Markets

IndiaGlobal

Why This Company Matters

Biocon is making expensive biologic drugs accessible to millions of patients worldwide through affordable biosimilars, reshaping global pharmaceutical economics.

Key Focus Areas

BiosimilarsInsulinOncology BiologicsImmunology

Peer Companies

View all

BeiGene

6 signals

China's largest global biotech company focused on innovative oncology medicines

Beijing, China

Celltrion

2 signals

South Korea's leading biosimilar manufacturer challenging global pharma giants

Incheon, South Korea

Daiichi Sankyo

0 signals

Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)

Tokyo, Japan

Doctor Anywhere

0 signals

Southeast Asia's leading omnichannel healthcare platform

Singapore

Halodoc

2 signals

Indonesia's leading telehealth and health-tech platform

Jakarta, Indonesia

Healius

2 signals

Australia's second-largest private pathology and imaging provider

Sydney, Australia

Signal Activity

0This Month

0Last 30 Days

1Total

Signal Timeline

1 total

February 2026

PartnershipCanonicalFeb 7

Biocon Biologics Completes Integration of Viatris Biosimilars, Becomes World's Largest

Biocon Biologics has completed the integration of Viatris's biosimilars business, creating the world's largest pure-play biosimilars company with a portfolio of 20+ molecules and commercial presence in 120+ countries. The combined entity reported annualized revenue of $2.1 billion and aims to make biologics accessible to patients across emerging markets in Asia, Africa, and Latin America.

Get Biocon signal updates

Get notified when new signals are published for this company.

Explore More Industries

All Industries

AI & Frontier Intelligence49 signals Fintech & Digital Finance28 signals Mobility, EV & Autonomous Systems44 signals Energy, Climate & Industrial Transition34 signals